US-based implantable device maker Neuropace has secured $49m in funding, according to a filing with the US Securities and Exchanges Commission, from an overall planned offering of $62m.
Although the investors in the round were undisclosed, Neuropace previously raised $23m in funding, in September 2008, from Kleiner Perkins Caufield Byers (KPCB), Interwest Partners and Domain Associates.
Prior to that round, Neuropace’s series B round attracted $30m in financing, in 2005, from the above backers, as well as VC firms MedVenture Associates and NEA Technology Partners.
In addition, Neuropace counts corporate venturing unit Johnson & Johnson Development Corporation (JJDC) and VC firms DAG Ventures and Glynn Capital Management among its investors. Brad Vale, head of venture investments at JJDC, is one of the Neuropace directors listed on the recent filing.
Founded in 1997, Neuropace submitted an application to the US Food and Drug Administration for pre-market approval, in 2010, for its RNS System, designed to help epilepsy victims. The device works by detecting abnormal brain activity and using electrical stimulation to suppress epileptic attacks before they occur.